Fox Run Management, L.L.C. Halozyme Therapeutics, Inc. Transaction History

Fox Run Management, L.L.C.

11 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2024 Aug 13, 2024	SELL	$37.81 - $52.4 $447,972 - $620,835	-11,848 Reduced 70.32%	5,001 $261,000
Q1 2024 May 13, 2024	BUY	$33.68 - $41.95 $567,474 - $706,815	16,849 New	16,849 $685,000
Q3 2023 Nov 07, 2023	BUY	$36.46 - $44.03 $638,414 - $770,965	17,510 New	17,510 $668,000
Q2 2022 Aug 12, 2022	BUY	$37.35 - $48.3 $285,316 - $368,963	7,639 New	7,639 $336,000
Q1 2019 Oct 17, 2019	SELL	$13.94 - $17.58 $143,763 - $181,302	-10,313 Closed	0 $0
Q4 2018 Jan 15, 2019	SELL	$13.33 - $18.66 $102,001 - $142,786	-7,652 Reduced 42.59%	10,313 $151,000
Q3 2018 Oct 05, 2018	BUY	$16.68 - $18.41 $299,656 - $330,735	17,965 New	17,965 $326,000
Q2 2018 Jul 17, 2018	SELL	$16.87 - $20.3 $209,677 - $252,308	-12,429 Closed	0 $0
Q1 2018 Apr 17, 2018	SELL	$17.06 - $21.2 $442,126 - $549,419	-25,916 Reduced 67.59%	12,429 $243,000
Q4 2017 Jan 18, 2018	BUY	$16.75 - $20.8 $359,203 - $446,056	21,445 Added 126.89%	38,345 $777,000
Q3 2017 Oct 23, 2017	BUY	$11.76 - $17.4 $198,744 - $294,060	16,900	16,900 $294,000

543

125M

294K

180K

Ticker HALO
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 139,288,992
Market Cap $6.62B
Description
Halozyme Therapeutics, Inc. operates as a biopharma technology platform company in the United States, Switzerland, Ireland, Belgium, Japan, and internationally. The company's products are based on the ENHANZE drug delivery technology, a patented recombinant human hyaluronidase enzyme (rHuPH20) that enables the subcutaneous delivery of injectable...

Get notified when there are updates to the investment portfolio of Fox Run Management, L.L.C., based on Form 13F filings with the SEC.

Stay updated on Fox Run Management, L.L.C. with notifications on news.